Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications.
Melanoma
cancer survivors
drug-related side effects and adverse reactions
long term adverse effects
long-term care
melanoma, cutaneous malignant
proto-oncogene proteins B-raf
skin neoplasms
survivors
vemurafenib
Journal
The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
pubmed:
3
9
2020
medline:
10
6
2022
entrez:
3
9
2020
Statut:
ppublish
Résumé
The introduction of targeted therapies for the treatment of BRAF-mutated metastatic melanoma was associated with different cutaneous adverse events (AEs). To describe the type, frequency and severity of cutaneous AEs related to vemurafenib; to understand the association between AEs and vemurafenib efficacy in terms of median overall survival (OS) and median progression-free survival (PFS); to identify molecular characteristics of long-term responders. This observational, retrospective, monocentric study included all consecutive patients with unresectable stage III or stage IV melanoma and BRAF V600E mutation that started treatment with vemurafenib between May 2012 and May 2014. 62 patients with a median age of 56 years (range 26-82) were enrolled and received vemurafenib for a median period of 7.9 months (range 0.8-63.7). Among them, 45 patients presented at least one skin AE, 12 reduced the dosage due to cutaneous toxicity, and only one firstly reduced and after stopped the therapy. No specific molecular biomarkers were detected in long-term survivors. Among long-term survivors, skin AEs seem to be less frequent and less severe. Results on multivariable analysis revealed that the presence of at least one G2 toxicity is a protective factor considering PFS, but not in terms of OS.
Sections du résumé
BACKGROUND
UNASSIGNED
The introduction of targeted therapies for the treatment of BRAF-mutated metastatic melanoma was associated with different cutaneous adverse events (AEs).
OBJECTIVES
UNASSIGNED
To describe the type, frequency and severity of cutaneous AEs related to vemurafenib; to understand the association between AEs and vemurafenib efficacy in terms of median overall survival (OS) and median progression-free survival (PFS); to identify molecular characteristics of long-term responders.
METHODS
UNASSIGNED
This observational, retrospective, monocentric study included all consecutive patients with unresectable stage III or stage IV melanoma and BRAF V600E mutation that started treatment with vemurafenib between May 2012 and May 2014.
RESULTS
UNASSIGNED
62 patients with a median age of 56 years (range 26-82) were enrolled and received vemurafenib for a median period of 7.9 months (range 0.8-63.7). Among them, 45 patients presented at least one skin AE, 12 reduced the dosage due to cutaneous toxicity, and only one firstly reduced and after stopped the therapy. No specific molecular biomarkers were detected in long-term survivors.
CONCLUSIONS
UNASSIGNED
Among long-term survivors, skin AEs seem to be less frequent and less severe. Results on multivariable analysis revealed that the presence of at least one G2 toxicity is a protective factor considering PFS, but not in terms of OS.
Identifiants
pubmed: 32875931
doi: 10.1080/09546634.2020.1817838
doi:
Substances chimiques
Sulfonamides
0
Vemurafenib
207SMY3FQT
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM